BioSpace News Archive

T-Cure Bioscience, Inc. announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1, such as gastric, cervical, lung, breast cancers and other KK-LC-1 positive epithelial cancers.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences.

Caris Life Sciences® announced results from a study highlighting a strong association between CCR5/CCL5 gene expression and distinct molecular features including Consensus Molecular Subtype, tumor mutational burden, lymphocyte infiltration in the tumor microenvironment, as well as patient outcome, and treatment benefit in Colorectal Cancer.

Theravance Biopharma, Inc. announced strategic actions to focus on leveraging its expertise in developing and commercializing respiratory therapeutics in order to maximize shareholder value.

iPharma Labs, Inc., a privately-held contract development research organization specializing in inhalation pharmaceutical development services, announced the implementation of GMP services for release testing for inhalation clinical trials.

Eli Lilly and Company announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19.

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced that the Company will be present at the following upcoming virtual investor conferences in September:

Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for patients with severe pulmonary diseases, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug, Fast Track and Qualified Infectious Disease Product designations for opelconazole (PC945) for the treatment of invasive pulmonary aspergillosis (IPA).

Autolus Therapeutics plc today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021.

PYC Therapeutics today announced it will participate as one of a select group of companies at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, taking place virtually on September 20–23, 2021.